EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya

Emily T O'Neill, Andrew W Huang, Marta Wilson-Barthes, Imran Manji, Gabriel Kigen, Naftali Busakhala, Samuel Nyanje, Omar Galárraga, Sonak D Pastakia

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-025-01454-7 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Emily T O'Neill und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Policy and Practice, Brown University School of Public Health, 121 S. Main Street, Providence, RI, 02903, USA. Hauptthemen laut MEDLINE: Rivaroxaban, Warfarin, Venous Thromboembolism, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Access to direct oral anticoagulants (DOACs) in sub-Saharan Africa is limited due to prohibitive upfront costs, making warfarin the standard of care for many patients, especially those relying on public-sector healthcare. This study evaluated the cost-effectiveness of using the DOAC, rivaroxaban, compared to warfarin for treating venous thromboembolism (VTE), a cardiovascular disorder caused by blood clots in the veins, in western Kenya. METHODS: We developed a discrete-time individual state-transition Markov model to simulate a VTE patient's quality-adjusted life-years (QALYs) and annual treatment costs under a rivaroxaban or warfarin therapy strategy. Transition state probabilities were derived from real-world event-rate data observed in patients treated with rivaroxaban (n = 160) or warfarin (n = 116) for VTE at Moi Teaching and Referral Hospital in western Kenya. Base-case parameter values were obtained from cohort event rates, local costs, and literature-derived utility values. Cost-effectiveness was assessed over a 1-year time horizon using an incremental cost-effectiveness ratio (ICER) threshold of (US)$6020.40 per QALY gained (equivalent to three times Kenya's 2021 per capita GDP). Deterministic and probabilistic sensitivity analyses were conducted to assess parameter and model uncertainty. RESULTS: After 12 months, total mean treatment costs per patient were $216.00 and $173.00 using warfarin and rivaroxaban, respectively. In the base-case analysis, rivaroxaban therapy resulted in an additional 0.023 QALYs per patient compared to warfarin, with an ICER of $- 1862.00 per QALY gained. Based on probabilistic sensitivity analysis with Monte Carlo simulation, when costs, utility values, and event rates were varied, rivaroxaban was cost-effective compared to warfarin in 84.1% of all simulations at a willingness-to-pay threshold of $6020.40 per QALY. One-way sensitivity analyses and scenario analyses were stable with rivaroxaban therapy, resulting in fewer costs and higher QALYs. CONCLUSIONS: In this study, rivaroxaban is a clinically and economically superior alternative to warfarin. This research may catalyze further discussions with policymakers and industry partners to scale up the appropriate use of rivaroxaban in resource-constrained settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanWarfarinVenous ThromboembolismAnticoagulantsFactor Xa InhibitorsHumansCost-Benefit AnalysisKenyaQuality-Adjusted Life YearsMarkov ChainsFemaleMaleMiddle AgedCost-Effectiveness Analysis

Substanzen

RivaroxabanWarfarinAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Department of Health Services Policy and Practice, Brown University School of Public Health, 121 S. Main Street, Providence, RI, 02903, USA.
  • Center for Global Public Health, Brown University School of Public Health, 121 S. Main Street, Providence, RI, 02903, USA.
  • Directorate of Pharmacy and Nutrition, Moi Teaching and Referral Hospital, Eldoret, Kenya.
  • Department of Pharmacology and Toxicology, Moi University School of Medicine, Eldoret, Kenya.
  • Academic Model Providing Access to Healthcare (AMPATH), PO Box 4606-30100, Eldoret, Kenya.
  • Department of Pharmacy Practice, Purdue University College of Pharmacy, 640 Eskenazi Ave., Indianapolis, IN, 46202, USA. spastaki@purdue.edu.

Zitieren

APA

O'Neill, E. T., Huang, A. W., Wilson-Barthes, M., Manji, I., Kigen, G., Busakhala, N., Nyanje, S., Galárraga, O., & Pastakia, S. D. (2025). A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01454-7

Vancouver

O'Neill ET, Huang AW, Wilson-Barthes M, Manji I, Kigen G, Busakhala N, et al. A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01454-7

BibTeX
@article{ONeill2025,
  author = {O'Neill, Emily T and Huang, Andrew W and Wilson-Barthes, Marta and Manji, Imran and Kigen, Gabriel and Busakhala, Naftali and Nyanje, Samuel and Galárraga, Omar and Pastakia, Sonak D},
  title = {A Cost-Effectiveness Analysis of Rivaroxaban Compared to Warfarin for the Management of Venous Thromboembolism in Western Kenya},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-025-01454-7}
}
Kostenlos starten →